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Highlights 
 Feline blood monocytes specifically resemble human monocytes at a transcriptional 
level.  
 Monocytes from cats with T2D exhibit a distinct expression profile to control 
monocytes. 
 Expression profiling implicates stress and inflammatory pathways in the 
pathogenesis of T2D in cats  
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Abstract  
Diabetes mellitus is a common disease of cats and is similar to type 2 diabetes (T2D) in 
humans, especially with respect to the role of obesity-induced insulin resistance, glucose 
toxicity, decreased number of pancreatic β-cells and pancreatic amyloid deposition. Cats 
have thus been proposed as a valuable translational model of T2D. In humans, inflammation 
associated with adipose tissue is believed to be central to T2D development, and peripheral 
blood monocytes (PBM) are important in the inflammatory cascade which leads to insulin 
resistance and β-cell failure. PBM may thus provide a useful window to study the 
pathogenesis of diabetes mellitus in cats, however feline monocytes are poorly 
characterised. In this study, we used the Affymetrix Feline 1.0ST array to profile peripheral 
blood monocytes from 3 domestic cats with T2D and 3 cats with normal glucose tolerance. 
Feline monocytes were enriched for genes expressed in human monocytes, and, despite 
heterogeneous gene expression, we identified a T2D-associated expression signature 
associated with cell cycle perturbations, DNA repair and the unfolded protein response, 
oxidative phosphorylation and inflammatory responses. Our data provide novel insights into 
the feline monocyte transcriptome, and support the hypothesis that inflammatory monocytes 
contribute to T2D pathogenesis in cats as well as in humans. 
 
 
Abbreviations 
BCS Body condition score 
MBA Multiple biochemical analysis 
T2D Type 2 diabetes mellitus             
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PBMC Peripheral blood mononuclear cells 
PBM Peripheral blood monocytes 
RIN RNA Integrity Number 
ROS Reactive oxygen species 
Keywords: feline, diabetes mellitus, peripheral blood monocytes, microarray 
 
Introduction 
Diabetes mellitus is a common endocrine disease in cats; 1 in 200 domestic cats, and 1 in 
50 Burmese cats in Australia, are diabetic (Lederer et al., 2009; McCann et al., 2007). In 
cats the disease usually presents with polydipsia, polyuria, polyphagia, weight loss, 
hyperglycaemia and strong glucosuria (Reusch, 2010a). As affected cats are usually middle-
aged or older, concurrent disease may occur, particularly pancreatitis, hepatic lipidosis, 
cholangiohepatitis and inflammatory bowel disease. Common disorders occurring secondary 
to feline diabetes mellitus include urinary tract infection, renal disease and peripheral 
neuropathy (Scott-Moncrieff, 2010). 
 
Diabetes mellitus in cats is very similar to type 2 diabetes mellitus (T2D) in humans, 
especially with respect to the role of obesity-induced insulin resistance, glucose toxicity, 
decreased number of β-cells and pancreatic amyloid deposition (Osto et al., 2013; Zini, 
2009). Risk factors associated with development of T2D in cats include obesity, inactivity, 
genetic predisposition (Forcada et al., 2014), breed (O'Leary et al., 2013), increasing age, 
being a desexed male (McCann et al., 2007), and administration of glucocorticoids or 
megoestrol acetate (often administered to treat inflammatory disease, cancer or diseases 
with immune dysregulation). However, there is a lack of understanding of the genetic factors 
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and molecular mechanisms that predispose cats to developing T2D, determine the likelihood 
of disease progression, and contribute to the development of co-morbidities. 
 
Human patients with T2D exhibit insulin resistance associated with obesity and an 
inflammatory response, with increased reactive oxygen species (ROS) generation and 
oxidative DNA damage resulting from hyperglycaemia (Manoel-Caetano et al., 2012). 
Inflammation has been suggested to be the common mechanism linking glucotoxicity, 
lipotoxicity and β-cell dysfunction, and also contribute directly to the development of T2D-
associated complications such as retinopathy and nephropathy, and compromised tissue 
repair(Conde et al., 2010; Manoel-Caetano et al., 2012; McNelis and Olefsky, 2014; Meier et 
al., 2014). Adipose tissue in obese humans secretes chemoattractive factors which recruit 
monocytes and other leucocytes into adipose tissue, where they and their differentiated 
progeny, macrophages, secrete pro-inflammatory cytokines such as TNF, IL-6 and IL-1β that 
are implicated in driving the development of insulin resistance and T2D (Conde et al., 2010). 
Peripheral blood monocytes are thus implicated in the pathogenesis of T2D, and, because 
they circulate systemically and respond sensitively to environmental changes (e.g. 
hyperglycaemia and hyperlipidaemia), may reflect tissue damage and disease status. 
Several studies in T2D in humans investigating alterations in peripheral blood mononuclear 
cells, and monocytes in particular, support the activation of genes involved in mitochondrial 
oxidative phosphorylation, insulin signaling pathways, nuclear receptors, inflammatory and 
immune responses, responses to oxidative stress and hypoxia, fatty acid processing and 
DNA repair (Giulietti et al., 2007; Lackey and Olefsky, 2016; Liu et al., 2007; Manoel-
Caetano et al., 2012; Takamura et al., 2007). Other studies, however have failed to detect 
an inflammatory signature (Baldeon et al., 2015). Further studies are clearly required to 
define the pathogenic role of monocytes and the inflammatory pathophysiology of T2D. 
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Due to the similarities between human and feline T2D, this study aimed to improve 
understanding of feline T2D pathogenesis by investigating whether peripheral blood 
monocyte gene expression is a sensitive indicator of the diabetes microenvironment in cats. 
Despite knowledge of risk factors that make cats predisposed to diabetes, no early 
diagnostic screening tests are available, and no markers are known that predict which at-risk 
cats will progress to develop diabetes. Feline innate immune cells, including monocytes, are 
poorly characterised. Adipose tissue macrophages from obese cats, like obese humans, 
express IL-6 and IFNɣ, resembling the obesity induced phenotype switch of murine and 
human ATMs (Ampem et al., 2016). Feline monocytes can be differentiated ex vivo into 
potent phagocytic macrophages, in response to the growth factors Colony Stimulating Factor 
(CSF)-1 and Granulocyte Macrophage CSF (Gow et al., 2013; Sprague et al., 2005), and 
respond to inflammatory stimuli through Toll-like Receptor 4 with production of the 
inflammatory cytokine TNF (Tamamoto et al., 2013). However, to our knowledge the feline 
monocyte transcriptome has never been studied. We profiled monocyte gene expression in 
insulin-treated cats with T2D and controls and report a T2D-associated expression 
signature.  
 
Materials and Methods 
Case selection and collection of EDTA blood samples 
Three diabetic and three control cats were enrolled in this study. Clients of The University of 
Queensland Small Animal Veterinary Teaching Hospital who owned cats believed to have 
well-controlled diabetes mellitus were invited to participate. Diagnosis of diabetes was based 
on consistent clinical signs including polydypsia, polyuria, polyphagia, hyperglycaemia and 
glucosuria. The latter occurs when blood glucose exceeds the renal threshold, which is 
approximately 14-16 mmol/L in healthy cats (Martin, 2002). Cats with diabetes mellitus in 
this study had no clinical or laboratory evidence of other causes of insulin resistance such as 
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acromegaly, hyperadrenocorticism, or pancreatitis. Cats with acromegaly or 
hyperadrenocorticism typically require insulin doses in excess of 1.5 U/kg to control 
glycaemia and have other physical examination findings characteristic of their underlying 
disease (Reusch, 2010b). Of the diabetic cats enrolled in this study, one was Burmese, one 
a domestic medium hair, and one a Cornish Rex. Non-diabetic, control cats were Burmese 
and had been clinically characterised in a previous study which performed glucose tolerance 
testing to determine blood glucose reference intervals in healthy, client-owned cats. Casual 
(fasted or after feeding) blood glucose concentrations in healthy cats of a variety of ages and 
breeds rarely exceeded 6.5mmol/L (3 of 22 measurements) (Reeve-Johnson et al., 2012), 
suggesting 6.5 mmol/L is a stringent cut-point for determining normal blood glucose 
concentrations in client-owned cats, although published laboratory reference ranges often 
extend to 7 or 8 mmol/L (Reynolds et al., 2008). Control cats recruited for this study were of 
a similar age to diabetic cats, had a blood glucose concentration of up to 6.5 mmol/L, no 
history of insulin or oral hypoglycaemic therapy, and normal glucose tolerance (Reeve-
Johnson et al., 2013). Ethical approval was obtained from the University of Queensland 
animal ethics committee (Certificate ANRFA/SVS/530/12 and SVS/284/10). 
Animals were weighed and had body condition score (BCS) (laflamme, 1997) measured at 
the time of blood collection (5-6 mL collected from the jugular vein). Diabetic cats were fed 
and had insulin the morning of blood collection. Control cats were fasted the morning of 
blood collection. One mL of blood was preserved as serum for measurement of 
fructosamine, feline pancreatic lipase immunoreactivity (fPLIμ), total thyroxine (TT4) and 
multiple biochemistry analysis (MBA). A few drops of whole blood were used to measure 
glucose concentration using a handheld glucose meter calibrated for cats (Abbott 
AlphaTRAK). The remainder of the blood collected was preserved with EDTA as an anti-
coagulant, with 120 μL used to perform a complete blood cell profile and the residual for 
extracting peripheral blood monocytes (PBM).  
Isolation of peripheral blood monocytes 
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Feline peripheral blood monocytes were isolated from 3-5 mL of EDTA blood within 6 h of 
collection, using the MACS Whole Blood Column Kit, MACS Human Whole Blood CD14 
Microbeads and MACS separator (Miltenyi Biotec, Bergisch Gladbach, Germany) following 
the manufacturer’s protocol. The Miltenyi kit for isolating human monocytes employs the 
TUK4 anti-CD14 monoclonal antibody, which cross-reacts with feline CD14 (Bienzle et al., 
2003), in contrast to the commonly used MφP9 anti-CD14 clone, which did not cross-react 
with feline CD14 (unpublished data). Bead-isolated monocytes were stained with CD14-PE 
(TUK4, Miltenyi Biotec) to determine purity. Briefly, 5x105 monocytes were stained with anti-
CD14-PE for 20 minutes at room temperature in PBS containing 0.5% FCS and 0.01% 
NaN3, washed twice in PBS and analysed using a Gallios flow cytometer and Kaluza 
software (Beckman Coulter). Mean monocyte yield was 0.3 x 10(9)/L (sd = 0.3) or 300 x 
10(9) monocytes/mL blood.  
Total RNA extraction and microarray analysis 
Total RNA was extracted using the QIAGEN RNeasy Mini kit (QIAGEN, Germany) with on-
column DNase digestion according to the manufacturer’s protocol. Total RNA quantity and 
purity was evaluated using a NanoDrop spectrophotometer (A260/A280 values 1.94-2.06) 
prior to couriering samples to the Ramaciotti Centre UNSW for further quality control and 
microarray analysis. RNA Integrity Number (RIN) and ribosomal ratios were obtained using 
an Agilent 2100 Bioanalyzer, prior to RNA amplification and hybridisation to the Affymetrix 
GeneChip® Feline whole genome 1.0 ST Array. All hybridisations had consistent probeset 
means and AUC values ≥ 0.95 for the detection of positive over negative controls. The 
FelGene 1.0ST array, comprising 34,942 gene-level probe sets; a total of 792,191 probes 
(median 24 probes/gene) was designed in silico from genome reference sequence and 
Ensembl annotations and predictions on Feline genome version felCat3. Microarray data 
were normalised using Affymetrix Expression Console software using the RMA algorithm, 
and exported for further analysis in GeneSpring GX (Agilent). Data are available on the GEO 
website (https://www.ncbi.nlm.nih.gov/geo/), accession GSE92586. 
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Microarray and Pathway Analysis 
Differentially expressed probesets were identified by filtering for expressed probesets 
(Robust Multi-array Average (RMA)-normalised expression ≥8.8, the expression level of the 
Affymetrix BioB low expression control, in at least one sample), then selecting probesets that 
were differentially expressed between control and diabetic cats (p<0.05, students t-test; 
multiple testing correction was not applied due to the small number of samples and our goal 
to capture the scope of candidate differentially expressed genes in this analysis). Samples 
and differentially expressed probesets were clustered using the Spearman correlation with 
average linkage. Probesets identified as significantly up- or down-regulated in feline T2D 
peripheral blood monocytes were analysed for gene ontology enrichment using the 
Functional Annotation Clustering tool in DAVID (version 6.8, http://david.abcc.ncifcrf.gov/) 
with default settings. Gene Set Enrichment analysis (GSEA) was performed using GSEA v 
2.1 pre-ranked analysis (to identify transcripts enriched in feline monocytes compared to 
curated genesets, regardless of diabetes status) as well as standard analysis (using geneset 
permutation) to identify genesets enriched in T2DM compared to control monocytes.  
 
Results 
Clinical and biochemical features of study subjects 
There were 6 cats enrolled in this study; 3 cats with diabetes mellitus (all diagnosed more 
than 6 months previously) and 3 control cats. All were neutered. Clinical and laboratory 
results for the cats included in this study are shown in Table 1. T2D1 and T2D3 were not 
believed by their owners to currently show polyuria or polydipsia whereas the owner of 
T2D2, the only cat with a blood glucose concentration in excess of the reference interval, 
was not sure. T2D2 also had increased fructosamine concentration, supporting poor control 
of his diabetes (Hoenig et al., 2013). At the time of this study, no diabetic cats had feline 
pancreatitic lipase activity (fPLI) over 12 μg/dL, which is consistent with active pancreatitis 
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(Forcada et al., 2008; Reusch, 2010b). All control cats had fructosamine in the reference 
interval, consistent with good glycaemic control over the preceding 3 weeks, with no 
evidence of pancreatitis in 2 controls (fPLI concentrations < 12 μg/dL). The third control cat 
had a fPLi value of 22 μg/dL, however the significance of this finding is unknown as 
azotaemia may affect fPLi values, increased fPLi values are common in apparently healthy, 
normal cats, and the specificity of this test for pancreatitis is 63-91%(Lidbury and 
Suchodolski, 2016). Minor variations in biochemical analytes, with respect to reference 
intervals, were present in some cats (Table 1), none of which were considered significant, 
except for the increased urea in all diabetic cases, with one of these also showing 
inadequately concentrated urine (USG 1.018). These diabetic cases may thus have had 
some renal dysfunction. Blood differential analysis was within reference ranges for all cats 
(data not shown). 
 
Feline peripheral blood monocytes exhibit a monocyte-enriched transcriptional signature. 
Feline peripheral blood monocytes were directly isolated from whole blood using anti-human 
CD14 magnetic beads. Purified monocytes stained with anti-human CD14 (TUK4 clone 
employed in cell isolation) were analysed by flow cytometry to verify antibody cross-reactivity 
with feline CD14, and confirm the purity of the isolated population (Figure 1A). Total RNA 
was hybridised to the Affymetrix Feline GeneChip 1.0 ST Array microarray. Feline mRNA 
expression has previously been analysed by cross-hybridisation to human microarrays, as 
feline genes have generally >85% similarity to their human counterparts (Collison et al., 
2012; Dowling and Bienzle, 2005), and whole blood expression profiling has been performed 
using a custom cDNA array (Gao et al., 2013). To our knowledge, this is only the first report 
of feline monocyte transcriptional profiling, using a feline-specific microarray. 15,271 
probesets (of which 12,471 were assigned to 7,325 unique Ensembl or NCBI transcript IDs 
(6,368 annotated with a Gene Symbol), 1578 were assigned to predicted protein coding 
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Genscan scaffold sequences and 1,222 were completely unannotated) were detected above 
background. Upon unsupervised hierarchical clustering of detected probesets the 3 T2D 
subjects clustered together, away from the control subjects; whilst 2 of 3 control cats 
exhibited strikingly similar gene expression profiles (Figure 1B,C). Control #1 (the cat who 
had elevated fPLi (Table 1)), had a distinct expression profile, apparently with features of 
both the control and diabetic profiles. Principal Component Analysis confirmed Control #1 as 
an outlier (explaining 39.2% of the variance in the dataset), with diabetes status driving the 
2nd principal component (explaining 25.6% of the variance). Overall, Control #1’s monocyte 
expression profile was more closely correlated to the diabetic than control cats (Figure 1B).  
 
Gene Set Enrichment analysis (GSEA) was performed to identify genes enriched in feline 
monocytes, regardless of diabetes status, compared to known immunologic gene signatures 
(Molecular Signature (MSIG) database collection 7, comprising 4,872 genesets representing 
immune cell states and perturbations). Human monocyte expression signatures, identified in 
comparison to other major leukocytes including B and T lymphocytes, dendritic cells, 
neutrophils and macrophages were highly enriched in feline monocytes (Table 2). The 
enrichment of the steady state monocyte expression signature, compared to LPS-stimulated 
monocytes, suggests the absence of a strong inflammatory signature in the subject cats. 
Interrogating the highly curated “hallmark” collection, a set of 50 genesets representing 
defined biological states or processes, we found that feline monocyte-expressed genes were 
highly enriched for targets of the transcription factor c-MYC, and a range of biological 
pathways, including oxidative phosphorylation, MTOR signalling, TNF and interferon 
signalling (Table 2). 
 
T2D associated gene expression signature in feline peripheral blood monocytes. 
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314 probesets (208 of which were assigned gene symbols and mapped to 187 unique 
genes) were significantly differentially expressed between cats with T2D and control cats 
(p<0.05), the majority of which (77%) were relatively over-expressed in diabetic cats 
(Supplementary Table 1). Several unannotated non-coding RNA transcripts were 
represented among the most strongly enriched probesets in both T2D and control 
monocytes (Supplementary Table 1). The top differentially expressed probesets with 
annotated Gene Symbols are listed in Table 3). Hierarchical clustering of differentially 
probesets illustrates the consistency in the T2D-associated transcriptional signature 
identified, despite expression variability among the cats (in particular Control #1), which is 
also reflected in the relatively low average fold changes observed in expression (Figure 2). 
To gain insight into pathways that are dysregulated in feline T2D monocytes we used two 
approaches, both of which are limited to the subset of probesets with Gene Symbol 
annotations, since gene ontology classification and expression signatures available for 
comparison are largely based on human (or mouse) genes. First, we sought to identify 
pathways and gene ontology terms that were significantly over-represented among T2D-
upregulated genes, compared to their representation in the human genome. Several clusters 
of related ontology terms (terms are clustered according to similarity in gene membership to 
avoid redundancy) were enriched in the T2D expression signature, including terms 
associated with TGFB signalling, cell division, ubiquitination and phagocytosis (Table 4). The 
set of annotated genes that was relatively over-expressed in control compared to T2D 
monocytes was too small to perform gene ontology analysis.  
 
Secondly, we used gene set enrichment analysis (GSEA), which takes the transcriptome-
wide gene list ranked by expression in T2D v control monocytes and identifies genesets 
associated with cell states or biological pathways that are significantly enriched in each 
phenotype. T2D monocytes showed enrichment of a number of curated “hallmark” genesets 
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compared to control monocytes, including E2F targets and genesets associated with 
allograft rejection, cell cycle, DNA repair and the unfolded protein response (Table 5). 
Surprisingly, the most highly enriched immunologic gene signatures were associated with T 
lymphocyte differentiation and activation, perhaps corroborating the allograft rejection 
signature. A set of genes upregulated in PBMC from human T2D patients compared to 
healthy controls was also enriched in the feline monocyte T2D profile. Few genesets were 
significantly enriched in control monocytes compared to T2D monocytes. Control monocytes 
were, however, strongly enriched for the Interferon alpha response geneset (2.07, FDR 
<0.001), and a number of the enriched immunologic genesets also supported an interferon 
response (e.g. viral activation, data not shown).  
Given Control #1 clearly clustered away from all the other samples at a transcriptome-wide 
level, whilst the T2D subjects clustered together (Figure 1C), we also performed geneset 
enrichment analysis after excluding Control #1. This analysis identified similar genesets to 
those identified using the whole dataset, but additionally indicated an enrichment in 
genesets associated with the inflammatory response, including LPS activation of monocytes 
and Toll-like Receptor (TLR) signaling (Table 5). Interestingly, consistent with the higher 
correlation between Control #1 and diabetic cats compared to control cats, when compared 
to Controls #2 an #3, Control #1’s monocyte expression profile showed strong enrichment 
for similar genesets to those identified in the T2D subjects, including TNF signalling via 
NFKB, MTORC1 signaling and the inflammatory response (data not shown).   
 
 
Discussion 
We report the first transcriptomic study of cat monocytes, confirming their similarity to human 
monocytes, and specific signature compared to other peripheral blood leukocytes and 
differentiated macrophages. Monocytes and macrophages play critical roles in the 
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inflammatory cascade leading to insulin resistance, tissue damage and T2D, and represent 
potential targets for therapy. Circulating monocyte phenotype or function may also serve as 
a biomarker of disease status and progression. 
 
T2D cats exhibited a distinct expression profile, clearly clustering together at a whole 
transcriptome level. Statistical analyses of differentially expressed genes were, however, 
hampered by the fact that Control #1 exhibited an apparent inflammatory profile, which 
shared similarities with both control and diabetic cats. Control #1 had an elevated fLPI, 
suggestive of pancreatitis, however histologic lesions consistent with pancreatitis are 
common in apparently clinically normal, healthy cats and are not always associated with 
elevated fLPI (Bazelle and Watson, 2014; Gilor et al., 2016; Lidbury and Suchodolski, 2016; 
Oppliger et al., 2016). The significance of these findings in cats is unknown. However, 
clarification of the pathogeneses of these diseases, and the relationship between 
pancreatitis and T2D in cats could shed light on the utility of diagnostic tests and the clinical 
significance of various diagnostic test results in healthy and sick cats. 
 
Despite variation in monocyte gene expression between control cats, in particular, we 
identified a T2D-associated gene expression signature supporting the role of similar 
pathways to those identified in humans, including oxidative phosphorylation, DNA repair and 
the unfolded protein stress response, although there was little overlap between specific 
differentially expressed genes and those reported in human studies. After excluding Control 
#1 from our analyses, we identified enrichment of additional, inflammation-associated 
genesets in the T2D subjects (several of which were shared with Control #1). Together, 
these data suggest monocyte inflammatory and stress responses are activated in feline T2D, 
as has been observed in humans (Manoel-Caetano et al., 2012; van der Pouw Kraan et al., 
2015). The interferon signature identified in control monocytes, on the other hand, may 
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indicate a role for suppressed anti-viral capacity in the etiology of diabetes, as has previously 
been suggested (van der Pouw Kraan et al., 2015). T2D monocytes were also enriched for a 
set of genes that were upregulated in PBMC from T2D patients compared to healthy 
controls, further supporting parallels between disease pathogenesis in the species.  
 
Unexpectedly, pathway analysis suggested feline T2D monocytes upregulate expression of 
genes typically involved in T lymphocyte activation. The relevance of this is unclear, however 
we do not believe this is the result of contamination during monocyte purification, given the 
strong monocyte expression signature observed in the whole dataset. The strong enrichment 
of targets of the transcription factor c-MYC, an integral cell cycle regulator that is 
downregulated during terminal differentiation of many cell types, including monocytes(Huber 
et al., 2014), in feline monocytes may suggest that cat monocytes, unlike human monocytes, 
retain proliferative capacity. Moreover, the enrichment of cell cycle-associated genes, as well 
as target genes of the transcription factor E2F that has been linked to growth arrest in 
monocytes(Gutsch et al., 2011), suggests cell cycle dysregulation in T2D monocytes.  
 
T2D is common in domestic cats, but the molecular mechanisms are poorly understood and 
there are no biomarkers to predict the development and progression of the disease. Cats 
have also been proposed as a valuable translational model of T2D, due to the many features 
shared with human T2D (Osto et al., 2013), however limited tools are available for studying 
feline cellular molecular biology. Serum miRNA analysis has been employed to investigate 
markers of diabetes and hepatic steatosis using a murine microarray (Fleischhacker et al., 
2013; Weber et al., 2015), but alterations in circulating immune cells have not yet been 
investigated. The current study supports the utility of PBMC in investigating and describing 
the pathogenesis of T2D and pancreatitis in cats. 
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In conclusion, this study adds to our knowledge of innate immune cells and molecular 
mechanisms involved in the development of diabetes, in domestic short haired cats. 
Although ‘healthy’ feline monocyte expression in different breeds and settings has not been 
characterised, and was variable in this pilot study, we identified a consistent T2D signature 
in 3 domestic cats of different breeds with different levels of glycaemic control, associated 
with pathways known to be perturbed in human disease. We also note that the feline 
transcriptome is as yet poorly annotated, which limits the power of pathway analyses. This is 
a valuable dataset for the field of comparative immunology which enhances our 
understanding of cats as a translational model, and may contribute to the development of 
novel biomarkers and therapeutic approaches to prolong the lives of pets. 
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Figure Legends 
 
Figure 1. Feline peripheral blood monocyte expression profiling. (A) CD14 expression 
on purified feline peripheral blood monocytes. (B) Matrix showing Spearman correlations 
between control (Con) and diabetic (T2D) monocyte expression profiles. (C) Subjects and 
monocyte-expressed probesets (n=15,271) clustered by Spearman correlation.  
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Figure 2. Differential expression in Feline T2D monocytes. Subjects and probesets 
(n=314) that were differentially expressed between control (Con) and diabetic (T2D) 
monocytes were clustered by Spearman correlation. 
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Tables 
Table 1: Clinical and biochemical characteristics. Values outside the reference ranges1 
indicated in parentheses, are shown in bold. P-values were generated using a 2-tailed t-test. 
  Control1 Control2 Control3 T2D1 T2D2 T2D3 
p-
value 
Breed Burmese  Burmese Burmese Burmese DMH 
Cornish 
Rex 
 
Sex (all neuter) M F M M M M  
age (y)  12 12 12 15 13 14 0.026 
wt (kg) 5.7  4.5 6.4 5.6 5.4 7.7 0.49 
Body Condition 
Score 
(1-9)  
 6 6 7 6 5 7 
0.64 
SQ insulin dose 
(bid glargine) 
no no no 1 U 1.5 U 1.5 U 
 
Blood glucose 
mmol/L 
[3.9-7.5] 
 6.5 6.4 5.3 6.3 30.4 7.6 
0.33 
urine glucose2 no no no n.d. n.d. no  
fPLi ug/L 
[0.1-<3.5ug/L]3 
 22 6.8 5.3 10.7 3 4.2 
0.41 
TT4 nmol/L 
(9.5-48) 
 31 22.9 21.5 19.7 13.9 31.8 
0.61 
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Fructosamine 
umol/L 
[225-265 umol/L] 
243  216 221 295 604 204 
0.31 
urea mmol/L 
(5.4-10.7) 
 10.5 11.9 9.4 15.9 15.5 18.5 
0.007 
creatinine umol/L 
(70-160) 
 150 104 103 117 112 155 
0.69 
Ca mmol/L 
(1.75-2.5) 
 2.3 2.27 2.39 2.49 2.53 2.5 
0.008 
PO4 mmol/L 
(1.29-2.26) 
 0.9 1.09 1.1 1.21 1.13 1.53 
0.13 
total protein g/L 
(56-80) 
 80 66 72 71 83 85 
0.31 
albumin g/L 
(22-35) 
 29 37 38 38 38 35 
0.48 
globulins g/L 
(28-48) 
 51 29 34 33 45 50 
0.61 
total BR umol/L 
(<10) 
 2 <1 <1 <1 <1 <1 
 
ALP U/L 
(5-80) 
 32 13 15 29 64 16 
0.35 
ALT U/L 
(5-80) 
 52 73 82 89 152 65 
0.29 
GGT U/L 
(<10) 
 0 <1 <1 <1 <1 <1 
 
AST U/L 
(10-60) 
 30 40 62 29 36 32 
0.29 
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CK U/L 
(50-300) 
 140 152 351 89 124 155 
0.27 
Cholesterol mmol/L 
(1.9-3.9) 
 2.9 4.5 6.1 7.1 5.5 3.9 
0.49 
Na mmol/L 
(147-156) 
 144 155 154 155 161 158 
0.15 
K mmol/L 
(3.8-4.6) 
 4.1 4.1 4.4 3.8 5.2 5.1 
0.33 
Cl mmol/L 
(115-123) 
 110 120 122 121 122 123 
0.28 
HCO3 mmol/L 
(16-24) 
 21 22 22 16 21 20 
0.16 
 
1 Unless otherwise noted reference intervals were from Vepalabs, 36 Balaclava St 
Woolloongabba QLD 4102 
2 Urine glucose measured by urine Multistix reagent strips (Ames) when cat had urine in the 
bladder at examination 
3 fPLi reference interval 0.1 - < 3.5 ug/L with active mild pancreatitis possible with 
concentrations over 12 (Forcada et al., 2008) 
DMH: domestic medium hair 
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Table 2. Geneset Enrichment analysis (GSEA) of the global feline monocyte 
transcriptome. NES: Normalised Enrichment Score. FDR: False Discovery Rate. 
 
GeneSet 
GeneSet 
Size 
NES p-val 
FDR q-
val 
Im
m
u
n
o
lg
ic
 S
ig
n
a
tu
re
s
 
GSE29618_Up in Monocytes v Naïve 
B Lymphocytes 
140 3.83 <0.001 <0.001 
GSE29618_Up in Monocytes v 
Plasmacytoid DC 
142 3.62 <0.001 <0.001 
GSE29618_Up in Monocytes v 
Myeloid DC 
139 3.59 <0.001 <0.001 
GSE22886_Up in Monocytes v Naïve 
T Lymphocytes 
137 3.52 <0.001 <0.001 
GSE9988_Downregulated in 
monocytes by LPS treatment 
150 3.28 <0.001 <0.001 
GSE22886_Up in Monocytes v 7-day 
cultured Monocytes (Macrophages) 
134 3.02 <0.001 <0.001 
GSE22886_Up in Monocytes v 
Neutrophils 
152 2.98 <0.001 <0.001 
H
a
ll
m
a
rk
 
MYC targets 148 3.34 <0.001 <0.001 
Oxidative Phosphorylation 146 3.07 <0.001 <0.001 
MTORC1 Signaling 154 2.68 <0.001 <0.001 
TNFA Signaling via NFkB 126 2.61 <0.001 <0.001 
Interferon Alpha Response 64 2.54 <0.001 <0.001 
Unfolded Protein Response 88 2.51 <0.001 <0.001 
Interferon Gamma Response 133 2.48 <0.001 <0.001 
Protein Secretion 76 2.47 <0.001 <0.001 
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IL6/JAK/STAT3 Signaling 60 2.43 <0.001 <0.001 
PI3K/AKT/MTOR Signaling 83 2.34 <0.001 <0.001 
DNA Repair 116 2.33 <0.001 <0.001 
Adipogenesis 147 2.26 <0.001 <0.001 
P53 Pathway 141 2.25 <0.001 <0.001 
TGFB Signaling 36 2.17 <0.001 <0.001 
Apoptosis 107 2.13 <0.001 5.9E-05 
Reactive Oxygen Species Pathway 36 2.09 <0.001 1.1E-04 
Peroxisome 77 2.08 <0.001 1.1E-04 
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Table 3: Top 10 significantly overexpressed probesets assigned to Gene Symbols in T2D 
and control monocytes. 
Probeset 
ID 
Gene Symbol mRNA Accession 
Fold Change 
Control/T2D 
14620769 SH2D1A ENSFCAT00000008356 0.071 
14640264 ALAS2 ENSFCAT00000000908 0.284 
14535457 FXC1 ENSFCAT00000004633 0.372 
14616718 GPR125 ENSFCAT00000001550 0.418 
14598371 SLC9A9 ENSFCAT00000009301 0.520 
14615888 PLCG1 ENSFCAT00000009035 0.529 
14571381 UGGT1 ENSFCAT00000001265 0.535 
14616616 PHF5A ENSFCAT00000003676 0.543 
14534676 TXNDC16 ENSFCAT00000000462 0.544 
14660847 TSPAN18 ENSFCAT00000004187 0.553 
14594121 LSM6 ENSFCAT00000003047 1.466 
14536249 COG3 ENSFCAT00000004871 1.480 
14561018 TPM4 ENSFCAT00000009001 1.481 
14645967 VSIG4 ENSFCAT00000007041 1.658 
14637470 LRP8 ENSFCAT00000005933 1.694 
14579682 P2RY1 ENSFCAT00000013021 1.743 
14627820 MAP3K8 ENSFCAT00000004397 1.874 
14524268 LRP6 ENSFCAT00000000044 2.231 
14573976 HPSE ENSFCAT00000018807 2.240 
14557961 CCL3L NM_001163657 2.618 
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Table 4: Gene Ontology Enrichment Analysis. Functional clusters enriched among T2D 
upregulated genes. The enrichment score, calculated as the –log of the geometric mean of 
the enrichment p-values of the classification terms making up each cluster, is used to rank 
biological significance. 
Functional Cluster (Representative 
Term/s) 
Enrichment 
Score 
(Significance) 
Term Fold 
Enrichment 
(Range) 
TGFB signaling, negative regulation 1.8 2.0-9.2 
Cytoskeleton, mititotic cell division 1.75 2.4-5.1 
Ubiquitin conjugation pathway 1.69 1.2-9.8 
Golgi apparatus 1.64 1.4-2.5 
Endosome, Lysosome 1.56 2.5-6.0 
Fc-gamma receptor signaling, phagocytosis 1.44 1.4-8.0 
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Table 5. Geneset Enrichment in T2D feline monocytes. Selected genesets from MSIG 
hallmark, immunologic and KEGG pathway collections enriched in T2D compared to control 
monocytes.  
 
GeneSet Size NES P-VALUE FDR NES P-VALUE FDR
E2F Target Genes 147 2.17 <0.001 <0.001 1.75 <0.001 0.022
Allograft Rejection 128 2.14 <0.001 <0.001 1.28 <0.001 0.023
Cell Cycle: G2M Checkpoint 144 1.75 <0.001 0.010 1.58 0.003 0.032
Oxidative Phosphorylation 146 1.57 0.044 0.064 1.57 0.001 0.031
Cell Cycle: Mitotic Spindle 156 1.42 0.007 0.196 1.40 0.017 0.095
DNA Repair 116 1.40 0.006 0.182 1.00 0.462 0.602
Unfolded Protein Response 88 1.35 0.050 0.247 1.51 0.015 0.035
TNF signaling via NFKB 126 - - - 2.20 <0.001 <0.001
MTORC1 Signaling 154 - - - 1.75 <0.001 0.010
TGFB Signaling 36 - - - 1.56 0.023 0.032
Inflammatory Response 139 - - - 1.35 0.027 0.121
GSE22886_Up in Naïve T Cells v 
Monocytes 146 2.15 <0.001 <0.001 1.77 <0.001 0.005
GSE7509_Upregulated in DC by 
FCGRIIB stimulation 120 2.13 <0.001 <0.001 1.85 <0.001 0.002
GSE9006_Upregulated in T2D v 
Healthy PBMC at Diagnosis 129 1.39 0.027 0.074 1.46 0.019 0.099
GSE9988_Upregulated by LPS in 
Monocytes 115 - - - 1.95 <0.001 0.000
Primary Immunodeficiency 26 2.13 <0.001 <0.001 1.93 <0.001 0.017
Cell Cycle 85 1.97 <0.001 0.011 1.65 0.003 0.152
T Cell Receptor Signaling 82 1.90 <0.001 0.015 1.75 0.001 0.124
NK Cell Mediated Cytotoxicity 69 1.79 0.002 0.038 1.72 0.001 0.085
Ubiquitin-mediated Proteolysis 101 1.77 <0.001 0.039 1.29 0.067 0.516
Toll Like Receptor Signaling 65 - - - 1.50 0.021 0.384
All Samples Excluding Control #1
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